Carbocisteine Eg Granules For Oral Solution 10 Sachets

NAME
CARBOCYSTEIN EG 2.7 G GRANULATE FOR ORAL SOLUTION

PHARMACOTHERAPEUTIC CATEGORY
Expectorants, excluding associations with antitussives.

ACTIVE PRINCIPLES
Carbocysteine salt of lysine.

EXCIPIENTS
Mannitol, anhydrous citric acid, povidone, aspartame (E951), cedar flavor, orange flavor, granular orange.

INDICATIONS
Mucolytic, fluidifying in acute and chronic respiratory diseases.

CONTRAINDICATIONS / SECONDARY EFFECT
Hypersensitivity to the active substance or to any of the excipients; gastroduodenal ulcer; pregnancy and breastfeeding; pediatric patients (under 11 years).

DOSAGE
1 sachet a day. Any dose adjustments may relate to the frequency of administration or dose fractionation but must still be within the maximum daily dosage indicated. In consideration of the pharmacokinetic characteristics and the high tolerability, the recommended posology can be maintained even in patients with renal and hepatic insufficiency. Duration of treatment: carbocysteine lysine salt monohydrate can also be used for prolonged periods, in this case it is advisable to follow the doctor's advice. Dissolve the contents of the sachet in about half a glass of water, mixing well.

STORAGE
Store at a temperature not exceeding 30 degrees C.

WARNINGS
There are no known phenomena of addiction or dependence. The granulated drug for oral solution does not affect low-calorie or controlled diets and can also be administered to diabetic patients. The aspartame present in this medicine is a source of phenylalanine. It can be harmful to people with phenylketonuria.

INTERACTIONS
In controlled clinical trials no interactions have been highlighted with the most common drugs used in the treatment of upper and lower respiratory tract diseases, nor with food and with laboratory tests.

SIDE EFFECTS
The side effects that may occur with the medicine, classified by system organ (SOC), are as follows. Skin and subcutaneous tissue disorders: skin rash, urticaria, erythema, rash, bullous rash / erythema, pruritus, angioedema, dermatitis. Gastrointestinal disorders: abdominal pain, nausea, vomiting, diarrhea Nervous system disorders: vertigo. Vascular disorders: redness. Respiratory, thoracic and mediastinal disorders: dyspnoea. The reporting of suspected adverse reactions that occur after the authorization of the drug is important, as it allows continuous monitoring of the benefit / risk ratio of the drug.

PREGNANCY AND BREASTFEEDING
Although the active ingredient is neither teratogenic nor mutagenic and has not shown negative effects on reproductive function in animals, the drug should not be administered during pregnancy. Since 'no data are available on the passage of lysine monohydrate carbocysteinas in breast milk, use during lactation and' contraindicated.